Clinical trial
Perifosine in Treating Patients With Advanced Pancreatic Cancer
NCT00053924 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00053924 |
|---|---|
| Title | Perifosine in Treating Patients With Advanced Pancreatic Cancer |
| Official title | A Phase 2 Study Of Perifosine As Second Line Therapy For Advanced Pancreatic Carcinoma |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | perifosine |
| Start date | May 1, 2003 |
| Primary completion | May 1, 2006 |
| First posted | Feb 6, 2003 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: